Bordignon MB, Pesce Viglietti AI, Juliá EP, Sanchez MB, Rölle A, Mandó P, Sabatini L, Ostinelli A, Rizzo MM, Barrio MM, Mordoh J, Fainboim L, Levy EM. Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients. Cancer Immunol Immunother. (2023 in Press). doi: 10.1007/s00262-023-03448-w.      PubMed

Mordoh A, Triviño Pardo JC, Carri I, Barrio MM, Mordoh J, Aris M. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report. BMC Med Genomics. 16(1):1 (2023). doi: 10.1186/s12920-022-01426-2.      PubMed      Case Report

A, Aris M, Carri I, Bravo AI, Podaza E, Pardo JCT, Cueto GR, Barrio MM, J. An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases. Front Immunol. 13:842555 (2022). doi: 10.3389/fimmu.2022.842555. PubMed

Ruiz MS, Sánchez MB, Bonecker S, Furtado C, Koile D, Yankilevich P, Cranco S, Custidiano MDR, Freitas J, Moiraghi B, Pérez MA, Pavlovsky C, Varela AI, Ventriglia V, Sánchez Ávalos JC, Larripa I, Zalcberg I, Mordoh J, Valent P, Bianchini M. miRNome profiling of LSC-enriched CD34+CD38-CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool. Front Pharmacol. 11:612573 (2021). doi: 10.3389/fphar.2020.612573.      PubMed

Juliá EP, Mordoh J, Levy EM. Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer. Cells. 9(7):E1573 (2020). doi: 10.3390/cells9071573.      PubMed

Madorsky Rowdo FP, Barón A, Gallagher SJ, Hersey P, Emran AA, Von Euw EM, Barrio MM, Mordoh J. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long?term BRAF inhibition. Int J Oncol. 56(6):1429-1441 (2020). doi: 10.3892/ijo.2020.5031.      PubMed

Podaza E, Carri I, Aris M, von Euw E, Bravo AI, Blanco P, Ortiz Wilczyñski JM, Koile D, Yankilevich P, Nielsen M, Mordoh J, Barrio MM. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF. Front Immunol. 11:1147 (2020). doi: 10.3389/fimmu.2020.01147.       PubMed

Ruiz MS, Sánchez MB, Bonecker S, Furtado C, Koile D, Yankilevich P, Cranco S, Custidiano MDR, Freitas J, Moiraghi B, Pérez MA, Pavlovsky C, Varela AI, Ventriglia V, Sánchez Ávalos JC, Larripa I, Zalcberg I, Mordoh J, Valent P, Bianchini M. miRNome profiling of LSC-enriched CD34+CD38-CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool. Front Pharmacol. 11:612573 (2020). doi: 10.3389/fphar.2020.612573. eCollection 2020.      PubMed

Aris M, Bravo AI, Garcia Alvarez HM, Carri I, Podaza E, Blanco PA, Rotondaro C, Bentivegna S, Nielsen M, Barrio MM, Mordoh J. Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood. Front Immunol. 10:2213 (2019). doi: 10.3389/fimmu.2019.02213.      PubMed

Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunol Immunother. 68(10):1585-1596 (2019). doi: 10.1007/s00262-019-02391-z.      PubMed

Mac Keon S, Bentivegna S, Levy EM, Marks MS, Mantegazza AR, Wainstok R, Mordoh J. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model. Vaccine. 37(35):4947-4955 (2019). doi: 10.1016/j.vaccine.2019.07.018.      PubMed

Aris M, Bravo AI, Pampena MB, Blanco PA, Carri I, Koile D, Yankilevich P, Levy EM, Barrio MM, Mordoh J. Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report. Front Immunol. 9:955 (2018). doi: 10.3389/fimmu.2018.00955.      PubMed

Juliá EP, Amante A, Pampena MB, Mordoh J, Levy EM. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol. 9:2140 (2018). doi: 10.3389/fimmu.2018.02140.      PubMed

Pampena MB, Cartar HC, Cueto GR, Levy EM, Blanco PA, Barrio MM, Mordoh J. Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants. Front Immunol.;9:2531 (2018). doi: 10.3389/fimmu.2018.02531.      PubMed

Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac Keon S, Yépez Crow M, Bravo AI, O'Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM. Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Front Immunol. 8:625 (2017). doi: 10.3389/fimmu.2017.00625.      PubMed